Cancer survivorship: an integral part of Europe's research agenda

Lagergren, Pernilla; Schandl, Anna; Aaronson, Neil K.; Adami, Hans‐Olov; Lorenzo, Francesco De; Denis, L.; Faithfull, S; Liu, Lifang; Meunier, Françoise; Ulrich, Cornelia M.

doi:10.1002/1878-0261.12428

Cited by 118 publications

(111 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Long-term adverse effects have consequences for patients' physical, mental and social health. A review by the former EACS Taskforce on Cancer Survivorship was recently published [56] where survivorship was defined as the phase after active cancer treatment. Survivorship research-the last component of the cancer research continuum and an integrated part of the translational research-has a bearing on the evaluation of multiple outcomes, including symptom burden, functional health, health-related quality of life and socio-economics.…”

Section: Survivorship Researchmentioning

confidence: 99%

Towards a cancer mission in Horizon Europe: recommendations

et al. 2020

Self Cite

View full text Add to dashboard Cite

A comprehensive translational cancer research approach focused on personalized and precision medicine, and covering the entire cancer researchcare-prevention continuum has the potential to achieve in 2030 a 10-year cancer-specific survival for 75% of patients diagnosed in European Union (EU) member states with a well-developed healthcare system. Concerted actions across this continuum that spans from basic and preclinical research through clinical and prevention research to outcomes research, along with the establishment of interconnected high-quality infrastructures for translational research, clinical and prevention trials and outcomes research, will ensure that science-driven and social innovations benefit patients and individuals at risk across the EU. European infrastructures involving comprehensive cancer centres (CCCs) and CCC-like entities will provide researchers with access to the required critical mass of patients, biological materials and technological resources and can bridge research with healthcare systems. Here, we prioritize research areas to ensure a balanced research portfolio and provide recommendations for achieving key targets. Meeting these targets will require harmonization of EU and national priorities and policies, improved research coordination at the national, regional and EU level and increasingly efficient and flexible funding mechanisms. Long-term support by the EU and commitment of Member States to specialized schemes are also needed for the establishment and sustainability of trans-border infrastructures and networks. In addition to effectively engaging policymakers, all relevant stakeholders within the entire continuum should consensually inform policy through evidencebased advice.

show abstract

Section: Survivorship Researchmentioning

confidence: 99%

Towards a cancer mission in Horizon Europe: recommendations

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Long-term follow-up of treated cancer patients is another unmet need that is discussed in the article by Lagergren et al (2019) (gap 5, Fig. 1).…”

Section: The Cancer Research Continuum For Therapeuticsmentioning

confidence: 99%

Translational cancer research – a coherent cancer research continuum

Ringborg

2019

Molecular Oncology

View full text Add to dashboard Cite

The main components of the cancer research continuum are basic/preclinical research, early and late clinical research and, after the adoption of an innovation by the healthcare or health organisations, outcomes research. Translational cancer research, defined as a coherent cancer research continuum, is mandatory to address the increasing burden of cancer effectively. The growing cancer problem can only be significantly modified by concerted action involving prevention to decrease incidence, early detection and treatment to increase the cure rate, and personalised/precision cancer medicine to adapt early detection and treatment to the biology of a tumour with the aim of increasing the cure rate, prolonging survival and improving health‐related quality of life. By definition, translational cancer research for therapeutics has a focus on patients’ needs and for prevention for individuals at‐risk. Consequently, to increase the effectiveness of translational research, the different components of the cancer research continuum need to be better connected to the fundamental aim of a mission‐oriented approach to cancer (Celis and Pavalkis, 2017 ).

show abstract

“…These interventions would also widely support social participation through recovery in the physical, cognitive, emotional, and interpersonal domains of functioning, which may have declined during cancer treatment [24]. To date, multidisciplinary approaches including a combination of physical exercises, patient education, counselling, behavioural training and/or vocational counselling, have shown a moderate level of effectiveness in promoting RTW for individuals with cancer and other chronic conditions [25][26][27][28]. To be effective, these approaches need to be personalized to the individual and contextualized to the social and organizational environment [26,28].…”

Section: Introductionmentioning

confidence: 99%

A Social-Healthcare Pathway to Facilitate Return to Work of Cancer Survivors in Italy: Implementation Process of the UNAMANO project

Paltrinieri

Ricchi

Mazzini

et al. 2019

Preprint

View full text Add to dashboard Cite

Purpose Return to work (RTW) is a major goal to promote cancer survivors’ social participation. A multidisciplinary social-healthcare pathway called UNAMANO was designed to support RTW in this population. Methods UNAMANO was developed by the Azienda USL – IRCCS di Reggio Emilia (RE), in partnership with the local branch of the Italian Medical Association, nonprofit associations, vocational training institutions, social cooperatives, a labour union, and a chartered accounting firm. Results UNAMANO is directed towards employed individuals diagnosed with cancer living in the Province of RE. It has been implemented through four actions: A) healthcare professionals training on work-related occupational rehabilitation; B) dissemination among community and stakeholders; C) recruitment and training of volunteers; D) cancer survivor engagement and provision of a personalized comprehensive intervention. This consists in providing information and occupational therapy to overcome barriers and facilitate RTW or social support through re-training and tailored job search strategies for individuals based on their risk of job loss. Conclusions UNAMANO is the first Italian multidisciplinary social-healthcare pathway supporting RTW of cancer survivors. Addressing a wide area of cancer survivors’ needs, it provides personalized intervention to resolve work-related issues. We propose this patient-centred RTW model to promote an easier transition from hospital to community.Implications for cancer survivors UNAMANO can positively impact on cancer survivors’ health and well-being and can be provided at any stage of disease and treatment. UNAMANO ensures that RTW is coherent with cancer survivors’ health condition and expectations.

show abstract

Cancer survivorship: an integral part of Europe's research agenda

Cited by 118 publications

References 84 publications

Towards a cancer mission in Horizon Europe: recommendations

Towards a cancer mission in Horizon Europe: recommendations

Translational cancer research – a coherent cancer research continuum

A Social-Healthcare Pathway to Facilitate Return to Work of Cancer Survivors in Italy: Implementation Process of the UNAMANO project

Contact Info

Product

Resources

About